Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics, Inc. recently disclosed information revealing the latest advancements in its targeted antitumor virotherapies. The company’s press release, titled “Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer,” was issued on November 18, 2024. The data was presented at two prominent events, the International Oncolytic Virotherapy Conference and the Society for Immunotherapy of Cancer Annual Meeting, showcasing the capabilities of its proprietary RTNova™ systemic enveloped virotherapy technology.

RTNova is specifically engineered to address challenges in systemic virotherapy by incorporating enveloped technology into its tumor-selective vaccinia virus platform. This enhancement allows RTNova to potentially target multiple metastatic tumor sites, offering a promising approach in treating various oncology indications, including metastatic lung cancer. The data supports the transformation of tumor microenvironments, highlighting the therapeutic potential of Calidi’s enveloped virotherapies both as a monotherapy and a viral vector for delivering therapeutic gene or medicine payloads to tumor sites.

Dr. Santidrian, Chief Scientific Officer of Calidi Biotherapeutics, emphasized the significant progress made with the RTNova technology in advanced lung metastasis models. The presented data outlines how RTNova effectively kills and transforms tumor microenvironments, potentially revolutionizing the treatment of previously untreatable metastatic diseases.

The novel RTNova technology utilizes a tumor-selective strain of vaccinia virus to produce extracellular enveloped viruses (EEVs), allowing targeted delivery to tumor sites while evading rapid immune system clearance. This innovation expands RTNova’s utility as both a direct antitumor modality and a viral vector for customized cancer treatment delivery, opening avenues for potential collaborations with pharmaceutical partners.

Calidi Biotherapeutics remains committed to advancing its clinical-stage virotherapies, with a focus on developing multi-modal systemic antitumor treatments that can disrupt tumor growth, modify the tumor immune microenvironment, and achieve lasting therapeutic outcomes for a broader patient population.

Please visit the Calidi Biotherapeutics website for more information on the company’s innovative approaches in immuno-oncology and its mission to arm the immune system against cancer.

This article may contain forward-looking statements subject to risks and uncertainties. For further details and investor information, please refer to the official reports filed by Calidi Biotherapeutics with the Securities and Exchange Commission.

For further investor inquiries, please contact Dave Gentry, CEO of RedChip Companies, Inc., at [email protected].

Source: Calidi Biotherapeutics, Inc.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Calidi Biotherapeutics’s 8K filing here.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.